Awad Youssef Zeid

1983er, cardiologist.

[Awad Youssef Zeid @AwadZei1]

@hishamezzalarab والله ياحاج هشام انت وبنكك زي الفل

[Awad Youssef Zeid @AwadZei1]

@IsraelArabic معلش

[Awad Youssef Zeid @AwadZei1]

@Misa_Roumi معلش

[Awad Youssef Zeid @AwadZei1]

@YhudiHbaba99 معلش.

[Awad Youssef Zeid @AwadZei1]

@Ro_gopa ماتت الانسانيه من زمن

[Awad Youssef Zeid @AwadZei1]

@Dr_mira_yaftah انظري الي غزه

[Awad Youssef Zeid @AwadZei1]

@TawfikOkasha_ ولا يهمك يا دكتور توفيق

[Awad Youssef Zeid @AwadZei1]

@RassdNewsN @gork

[SAPH l المجموعة السعودية لضغط الشريان الرئوي @SAPH_NEWS]

Reflecting on SAPH2026,

Day 2 of the Conference continued the scientific momentum with high-level plenary sessions and multidisciplinary discussions that deepened the academic dialogue in pulmonary vascular medicine. The program featured comprehensive presentations addressing evolving standards of care, emerging therapeutic strategies, complex case management, and key research updates in pulmonary hypertension. These sessions enabled meaningful exchange among experts and reinforced alignment with contemporary international guidelines.

Distinguished national and international faculty contributed to focused discussions highlighting advances in clinical pathways, targeted therapies, and practical approaches to optimizing patient outcomes. The breadth and depth of the day’s program reflected the strength of the scientific agenda and the collective commitment to advancing specialized care.

Day 2 concluded with continued engagement across disciplines, sustaining the conference’s scientific rigor and professional collaboration.

#SAPH2026

[Dr. Chacón-Lozsán F .'. @franciscojlk]

#ESC75Years #CVHealthForAll #LetsRise2025 #ESCCongress
@ACVCPresident @PabloJ @drdargaray @drmilicaa @RThachilMD @Hragy @HannahSchaubro1 @rafavidalperez @veramasloo

[Awad Youssef Zeid @AwadZei1]

#PH #ESCCongress

[Awad Youssef Zeid @AwadZei1]

#ESCCongress

[Awad Youssef Zeid @AwadZei1]

Pulmonary hypertension @milica_yb @EuroRespSoc #ESCCongress2025

[Yogesh Reddy @yreddyhf]

Gp 1 PH with high HFpEF probability have less clinical improvement with traditional PH therapy, compared to gp 1 PH + low HFpEF prob. Do we need more intensive PH therapy, sotatercept or HFpEF therapies for these pts? Many unknowns that need RCTs.
https://t.co/tgPfPBRbcL

[Hany Ragy @Hragy]

Reviving the “lost” art of RHC (Right Heart Cath) our course launches , the first presentation of many to come..
We are happy to collaborate with all those whose areas of practice need revival of RHC..
#CardioAlex2025

[dawood @solymaan]

#FreedomFlotilla #BreakTheSiege #FreeMadleen

[Countess 𓂆 🇦🇱 @Estrella7stella]

This man is documenting history through his art ♥️

[Pulmonary Hypertension News @PulmonaryNews]

The first participant has been dosed in Foresee's Phase 2 trial testing the experimental oral therapy mirivadelgat in people with PH-ILD. https://t.co/8ypdF0XzLW

[PHAEUROPE @EuropePHA]

Sometimes, it's PH 🦓
Yoko from Japan has been living with pulmonary arterial hypertension (PAH) for over 20 years. Despite the challenges, she continues to move forward with the help of oxygen, epoprostenol, and an unwavering sense of hope. ⤵️

[European Lung Foundation @EuropeanLung]

Pulmonary hypertension (PH) causes breathlessness and a fast heartbeat. It is often hard to diagnose because many people with PH have other health conditions.

Help us raise awareness and support those living with PH. 💡 Learn more: https://t.co/Ugz5RgsT9n